Lehman Initates Amgen with 'Overweight'
Lehman Brothers initiates the biotech sector with a positive sector view, and started coverage of Amgen (AMGN ), Genentech (DNA ), MedImmune (MEDI ) and Transkaryotic Therapies (TKTX ) with an overweight rating.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- This $14 Million Atlanta Home With Bunker Is ‘Safest in America’
- Separatists Pledge to Fight On After Spain Moves to Oust Catalan Leaders
- These Cities Make NYC Housing Look Dirt Cheap
- GE's New CEO Vows Sweeping Change After ‘Unacceptable’ Report
- Greenwich Mansion Listings Pulled to Wait for a Better Day